Introduction
============

Follicular lymphoma (FL) is one of the most common types of indolent B-cell lymphoma in Western countries and accounts for approximately 25% of all non-Hodgkin lymphomas (Conconi et al., [@b4]). Despite a usually indolent clinical course with a long estimated survival of more than 10 years, FL is mainly incurable (Fisher et al., [@b7]). FL commonly transforms to the more aggressive diffuse large B-cell lymphoma (DLBCL) at reported frequencies between 15% and 60% of the included cases in various studies (Conconi et al., [@b4]). Even though a transformation is mainly seen from FL to DLBCL, transformation from other types of low malignant lymphomas to various types of biologically aggressive lymphoma has been reported (Montoto and Fitzgibbon, [@b16]). Transformation from FL to DLBCL (tDLBCL) is often accompanied by treatment resistance and poor survival. Although the treatment results of FL and de novo DLBCL (dnDLBCL), as well as tDLBCL, have improved over the years, the histological transformation from FL to tDLBCL remains a critical event in the FL progression. Insights into the evolution of the tumor cells (i.e., chromosomal aberrations, mutations, etc.) are highly warranted for early recognition of disease progression to clinically more aggressive forms.

Previous studies have shown that chromosomal aberrations are associated with histological transformation from FL to tDLBCL, such as loss of 1p36, 6q, and 17p and gains on 2p, 7, 12q13--14, and X (Martinez-Climent et al., [@b14]; Berglund et al., [@b1]; Lossos and Gascoyne, [@b13]). Genes such as *TP53*, *TP73*, *MDM2*, and *MYC* as well as *REL* (at 2p16) are often mentioned as possibly involved in the transformation pathogenesis. There are previous reports on 2p15--16 gain detected by genome-wide array-comparative genomic hybridization (CGH) in DLBCL (Martinez-Climent et al., [@b14]; Tagawa et al., [@b26]; Nanjangud et al., [@b17]). Amplification of 2p encompassing the *REL* gene has been detected in FL using quantitative real-time polymerase chain reaction (qPCR) and CGH (Goff et al., [@b9]).

Earlier reports on the molecular mechanism of transformation give little insight whether the transformation could be predicted by genetic alterations in the FL already at diagnosis or if the alterations occur in a minor subpopulation that is undetectable using current methodology. In this study, we attempted to elucidate the molecular mechanism behind the transformation from FL to the more aggressive tDLBCL. We have also included samples from patients with dnDLBCL to better pinpoint tDLBCL-specific features. We have analyzed patients with paired tumor samples with biopsies from both the FL stage of disease and the tDLBCL counterpart as well as nonpaired samples of tDLBCL. In three patients, we were able to study more than two subsequent tumors allowing us to follow the progression of specific genetic alterations acquired during the transformation process.

Materials and Methods
=====================

Patients and Clinical Samples
-----------------------------

The 81 tumor samples studied comprised 21 FL, 31 tDLBCL, and 29 dnDLBCL \[10 showing germinal center (GC) and 19 of non-GC related immunophenotype, Hans et al. ([@b10])\] collected from a total of 60 patients. Paired tumor samples, with both the FL as well as tDLBCL counterpart, were available from 15 patients (cases 44--51, 53, and 55--60). The tumors termed "FL prior to transformation" refer to the FL-tumors collected closest in time prior to the DLBCL-transformation (in cases 59 and 60 with more than two subsequent tumors of the FL counterpart). Clinical details are presented in Table[1](#tbl1){ref-type="table"}. DNA was isolated from frozen tumor samples and the patients were identified from medical files of the Departments of Pathology-Cytology at the Karolinska University Hospital, Solna, and Uppsala Academic Hospital, Sweden. Diagnostic material including immunohistochemical stains was reviewed according to the WHO 2008 classification (Campo et al., [@b3]), the tumors were not retrospectively analyzed regarding the presence of t(14;18)(q32;q21). The study of the clinical samples was approved by the Ethical Committee of the Karolinska University Hospital (No. 01--004) and Uppsala Academic Hospital (No. 2008/246).

###### 

Clinical Characteristics of the Included Patients

  Tumor no   Case no   Year   Age at diagn   Sex   Diagnosis   Institute    Transformed/De novo   GC/non-GC   Stage   Follow-up time (Mo)   Outcome                 Treatment
  ---------- --------- ------ -------------- ----- ----------- ------------ --------------------- ----------- ------- --------------------- ----------------------- --------------------------------------
  1          1         2007   86             M     DLBCL       Karolinska   Transformed           GC          II A    40                    DnL                     R-CHOP, MIME
  2          2         2007   51             F     DLBCL       Karolinska   De novo               Non-GC      IIIB    76                    relaps x 2, CCR         R-CHOP, SCT, DHAP
  3          3         2007   35             M     DLBCL       Karolinska   De novo               GC          II A    76                    CCR                     R-CHOP
  4          4         2007   46             M     DLBCL       Karolinska   De novo               GC          III B   1                     DoL                     R-MIME
  5          5         2007   61             M     DLBCL       Karolinska   De novo               Non-GC      III B   18                    relaps, DoL             R-CHOP, MIME SCT
  6          6         2006   29             F     DLBCL       Karolinska   Transformed           GC          IV A    83                    CCR                     R-CHOP, HDT, SCT
  7          7         2006   77             F     DLBCL       Karolinska   De novo               Non-GC      IV A    84                    CCR                     R-CHOP, RT
  8          8         2006   68             M     DLBCL       Karolinska   De novo               Non-GC      IIA     84                    CCR                     na
  9          9         2006   5              M     DLBCL       Karolinska   Relaps                GC          III     1                     DoL                     NHL BFM-90
  10         10        2005   91             F     DLBCL       Karolinska   De novo               GC          IA      70                    DnL                     WW, surgery
  11         11        2005   54             M     DLBCL       Karolinska   De novo               Non-GC      IA      91                    CCR                     R-CHOP
  12         12        2005   34             M     DLBCL       Karolinska   Transformed           GC          IIIA    97                    CCR                     R-CHOP
  13         13        2005   68             M     DLBCL       Karolinska   De novo               Non-GC      IIA     12                    DoL                     R-CHOP, CHVP
  14         14        2005   74             F     DLBCL       Karolinska   De novo               Non-GC      IIA     80                    DnL                     R-CHOP
  15         15        2005   87             F     DLBCL       Karolinska   De novo               Non-GC      IV      1                     DoL                     na
  16         16        2005   70             F     DLBCL       Karolinska   Transformed           GC          IV      14                    DoL                     R-CHOP, DHAP, MIME, Fludara, Cytosar
  17         17        2004   63             M     DLBCL       Karolinska   Transformed           GC          IIA     102                   CCR                     R-CHOP
  18         18        2004   62             F     DLBCL       Karolinska   De novo               GC          IIA     4                     DnL                     R-CHOP
  19         19        2004   51             M     DLBCL       Karolinska   De novo               Non-GC      IVA     108                   relaps, CCR             R-CHOP, MIME, HDT, SCT
  20         20        2004   56             M     DLBCL       Karolinska   De novo               Non-GC      IIIA    110                   CCR                     R-CHOP, Cytosar
  21         21        2004   74             F     DLBCL       Karolinska   Transformed           GC          IIIA    26                    relaps, DoL             R-CHOP, MIME
  22         22        2004   63             M     DLBCL       Karolinska   Transformed           GC          IV      104                   relaps, DoL             R-CHOP
  23         23        2003   63             F     DLBCL       Karolinska   Transformed           GC          IA      120                   CCR                     R-CHOP
  24         24        2002   59             M     DLBCL       Karolinska   De novo               na          IA      60                    CNS relaps, DoL         R-CHOP, RT
  25         25        2002   63             M     DLBCL       Karolinska   Transformed           GC          IV      15                    cutan relaps, DNL       R-CHOP
  26         26        2002   71             F     DLBCL       Karolinska   De novo               Non-GC      IIA     20                    DoL                     R-CHOP
  27         27        2002   63             M     DLBCL       Karolinska   De novo               Non-GC      IIB     113                   relaps, AML/MDS - DnL   R-CHOP, RT, R-MIME, SCT,
  28         28        2002   48             M     DLBCL       Karolinska   De novo               Non-GC      IIIB    133                   CCR                     R-CHOP
  29         29        2002   49             M     DLBCL       Karolinska   Transformed           GC          IA      20                    DoL                     R-CHOP
  30         30        2002   83             F     DLBCL       Karolinska   De novo               Non-GC      IIA     5                     DoL                     R-CHOP
  31         31        2001   67             F     DLBCL       Karolinska   Transformed           GC          IIA     38                    DoL                     R-CHOP, R-MIME, RT
  32         32        2001   13             F     DLBCL       Karolinska   De novo               Non-GC      IIA     139                   CCR                     NHL BF M 90
  33         33        2001   32             M     DLBCL       Karolinska   De novo               Non-GC      IA      140                   CCR                     R-CHOP, RT
  34         34        2001   83             M     DLBCL       Karolinska   De novo               Non-GC      IA      55                    DnL                     R-CHOP, splenectomy
  35         35        2001   62             M     DLBCL       Karolinska   Transformed           GC          IVA     143                   Relaps, CCR             R-CHOP, R-MIME, RT
  36         36        2001   60             F     DLBCL       Karolinska   De novo               GC          IVA     144                   CCR                     R-CHOP
  37         37        2001   56             F     DLBCL       Karolinska   De novo               GC          IA      150                   relaps, CCR             R-CHOP, DHAP, SCT
  38         38        2000   77             F     DLBCL       Karolinska   De novo               Non-GC      IIA     37                    relaps,DoL              R-CHOP, MIME, RT, Gemzar
  39         39        2000   81             M     DLBCL       Karolinska   De novo               GC          na      1                     DoL                     no treatment
  40         40        1999   77             F     DLBCL       Karolinska   De novo               Non-GC      IV      24                    DoL                     R-CHOP
  41         41        1999   55             M     DLBCL       Karolinska   Transformed           Non GC      IV      53                    DoL                     R-CHOP
  42         42        2004   63             F     DLBCL       Karolinska   De novo               GC          II      108                   CCR                     R-CHOP
  43         43:2      2007   66             M     DLBCL       Karolinska   Transformed           GC          IVB     71                    CCR                     R-MIME, SCT
  44         44:1      2001   31             M     DLBCL       Karolinska   Transformed           GC          IV      150                   CCR                     R-CHOP, MIME, Cytosar, autoSCT
  45         44:2      2003   33             M     FL III      Karolinska   na                    na          IIIA    0                     CCR                     MIME, alloSCT
  46         45:1      2001   49             M     FL I        Karolinska   na                    na          IV      32                    transformed to DLBCL    splenectomy
  47         45:2      2004   52             M     DLBCL       Karolinska   Transformed           GC          IV      70                    DoL                     R-CHOP, autoSCT, BEAM, DHAP, Gemzar
  48         46:1      na     37             M     FL n.a.     Uppsala      na                    na          na      na                    na                      na
  49         46:2      na     na             M     DLBCL       Uppsala      Transformed           GC          na      na                    na                      na
  50         47:1      na     61             M     FL II       Uppsala      na                    na          na      na                    na                      na
  51         47:2      na     na             M     DLBCL       Uppsala      Transformed           GC          na      na                    na                      na
  52         48:1      na     33             F     FL I        Uppsala      na                    na          na      na                    na                      na
  53         48:2      1992   33             F     DLBCL       Uppsala      Transformed           GC          IIIA    120                   CCR                     CHOP, ABMT
  54         49:1      1988   71             M     FL II       Uppsala      na                    na          na      90                    transformed to DLBCL    WW, chlorambucil
  55         49:2      1995   78             M     DLBCL       Uppsala      Transformed           GC          IVB     7                     DoL                     CHOP
  56         50:1      1994   69             F     FL I        Uppsala      na                    na          na      12                    na                      na
  57         50:2      1995   70             F     DLBCL       Uppsala      Transformed           GC          IVA     na                    na                      na
  58         51:1      1985   48             F     FL I        Uppsala      na                    na          na      60                    transformed to DLBCL    na
  59         51:2      1990   53             F     DLBCL       Uppsala      transformed           GC          IVB     21                    DoL                     CHOP
  60         52:1      1970   25             F     FL I        Uppsala      na                    na          na      247                   transformed to DLBCL    RT, Chlorambucil
  61         53:1      1991   50             F     FL I        Uppsala      na                    na          na      48                    transformed to DLBCL    Chlorambucil, CHOP
  62         53:2      1995   54             F     DLBCL       Uppsala      Transformed           GC          IVB     38                    DoL                     MIME
  63         54:2      1994   57             M     DLBCL       Uppsala      Transformed           GC          IVB     116                   CCR                     CT, ABMT
  64         55.1      1997   60             M     FL I        Uppsala      na                    na          na      14                    transformed to DLBCL    Chlorambucil
  65         55:2      1999   62             M     DLBCL       Uppsala      Transformed           GC          IIB     38                    CCR                     CHOP
  66         56:1      1984   71             F     FL I        Uppsala      na                    na          na      9                     transformed to DLBCL    RT
  67         56:2      1985   72             F     DLBCL       Uppsala      Transformed           GC          IIIB    4                     DoL                     COP
  68         57:1      na     60             F     FL I        Uppsala      na                    na          na      3                     transformed to DLBCL    splenectomy
  69         57:2      na     na             F     DLBCL       Uppsala      Transformed           GC          IVA     132                   DoL                     CHOP
  70         58:1      1992   51             F     FL I        Uppsala      na                    na          na      58                    transformed to DLBCL    CHOP, chlorambucil
  71         58:2      1997   56             F     DLBCL       Uppsala      Transformed           GC          IIIA    na                    progression             CT
  72         58:3      na     na             F     DLBCL       Uppsala      Transformed           GC          na      61                    DoL                     CT
  73         59:1      1992   39             F     FL I        Uppsala      na                    na          na      96                    progression             WW, chlorambucil, CHOP
  74         59:2      na     na             F     FL I        Uppsala      na                    na          na      na                    progression             WW, chlorambucil, CHOP
  75         59:3      na     na             F     FL II       Uppsala      na                    na          na      na                    transformed to DLBCL    WW, chlorambucil, CHOP
  76         59:4      2000   47             F     DLBCL       Uppsala      Transformed           GC          IIB     40                    DoL                     MIME
  77         60:1      1987   39             F     FL II       Uppsala      na                    na          na      148                   progression             WW, chlorambucil
  78         60:2      na     na             F     FL II       Uppsala      na                    na          na      na                    progression             WW, chlorambucil
  79         60:3      na     na             F     FL II       Uppsala      na                    na          na      na                    progression             WW, chlorambucil
  80         60:4      na     na             F     FL I        Uppsala      na                    na          na      na                    transformed to DLBCL    WW, chlorambucil
  81         60:5      1999   51             F     DLBCL       Uppsala      Transformed           GC          IVA     48                    DoL                     CT

Mo, months; M, male; F, female; na, not available; DnL, death not related to lymphoma; CCR, continous complete remission; DoL, dead of lymphoma; R, retuximab; CHOP, cyclophosphamide, vincristine, adriamycin, and prednisone; MIME, methyl-gag, iphosphamide, methotrexate, and epiposid; SCT, stem cell transplantation; DHAP, dexamethasone, ara-C, platinum; RT, radio therapy; NHL BFM-90, Berlin Frankfurt Munster protocol; WW, wait and watch; BEAM, carmustine, etoposide, cytarabine, melphalan; ABMT, high dose therapy with autologous stem cell rescue; COP, cyclophosphamide, vincristine, and prednisone; CT, different combination of chemotherapy.

The tumors from the Karolinska University Hospital (cases 1--45) are presented for the first time whereas the tumors from Uppsala (cases 46--60) were previously reported in a series of cases investigated by conventional CGH (Berglund et al., [@b1]). DNA was prepared from fresh frozen tumor samples using the QIAamp DNA Mini Kit (Qiagen, Valencia, CA) or a method based on Proteinase K digestion and phenol--chloroform extraction.

Construction of Genomic 1 Mb Array
----------------------------------

The 1-Mb array clone set was obtained from the Welcome Trust Sanger Institute, Hinxton, UK (Fiegler et al., [@b6]). Coordinates for the clones have been obtained from the Ensembl Genome Browser (<http://www.ensembl.org/Homo_sapiens>, release 27.35a. 1, NCBI 35 assembly, December 14, 2004). Clones which are mapped to more than one chromosome or which repeatedly showed inconsistent copy number in array-CGH analysis were excluded. As a result, a total of 3,038 clones (2555 BACs, 477 PACs, and six cosmids) were included in the analysis, giving an average distance between the clone midpoints of 0.97 Mb.

Construction of the microarray was performed essentially according to the published protocol with minor modifications (Fiegler et al., [@b6]). Briefly, clone DNA was extracted using a modified alkali lysis method (microprepping) and individually amplified using three different degenerate oligonucleotide (DOP)-PCR primers. The three DOP-PCR products for each clone were then mixed and amplified using a 5′-amine-modified universal primer (amino-PCR). The amino-PCR products were printed in duplicate onto CodeLink slides (Amersham Biosciences, Little Chalfont, UK) using a MicroGrid II robot (Genomic Solutions, Huntingdon, UK) in 4 × 6 subarrays. Further details of the microarray construction have been published elsewhere (McCabe et al., [@b15]).

Labeling and Hybridization of Array-CGH
---------------------------------------

Labeling and hybridization were performed essentially as previously described (Seng et al., [@b25]). Briefly, each microarray was prehybridized with 80 μg of Cot1 DNA (Roche Diagnostics, Mannheim, Germany) and 400 μg of herring sperm DNA (Sigma--Aldrich, St. Louis, MO) for 2 h in hybridization buffer \[50% formamide, 10% dextran sulfate, 0.1% Tween 20, 2× saline-sodium citrate (SSC), 10 mM Tris (pH 7.4)\]. Four-hundred nanograms of tumor and reference genomic DNA were labeled with Cy5-dCTP or Cy3-dCTP (Amersham Biosciences, Little Chalfont, UK), respectively, using a BioPrime Kit (Invitrogen, Palsely, UK) with custom-made dNTP mix (dCTP 1 mM, dATP 2 mM, dGTP 2 mM, and dTTP 2 mM). A mixture of normal blood DNA from either 20 males or 20 females was used as a sex-mismatched reference. The labeled and purified DNA from test and reference were mixed and coprecipitated with 45 μg of Cotl DNA and 200 μg of Herring sperm DNA. The precipitated DNA was dissolved in hybridization buffer, incubated at 37°C for 2 h and applied to the prehybridized microarrays. Hybridization was performed in a humidified Micro Array Hybridization Chamber (Camlab, Cambridge, UK) at 37°C for 24 h. The arrays were then washed successively in 1× Phosphate buffered saline (PBS)/0.05% Tween 20 at room temperature for 15 min twice, 50% formamide/2× SSC at 42°C for 30 min once, and 1× PBS/0.05% Tween 20 at room temperature for 15 min. Finally, the arrays were briefly rinsed in 1× PBS and dried by centrifugation. The arrays were scanned using a GenePix 4100A personal scanner (Axon Instruments, Union City, CA) and the images quantified using a GenePix Pro 5.1 (Axon Instruments) as previously described (Seng et al., [@b25]).

Array-CGH Data Analysis
-----------------------

The results were analyzed using Microsoft Excel, as described elsewhere (McCabe et al., [@b15]). Briefly, after exclusion of spots with weak Cy3 (reference) signals (less than four times the average intensity of six Drosophila BAC spots), the median of test/reference signal intensity ratio in each subarray was calculated and used as a normalization value. The test/reference ratio of each clone was then divided by the normalization value in each subarray, and an average of the normalized ratio between the duplicates was calculated. Spots were excluded when the duplicates differed by more than 10% from their average. The log~2~ values of normalized test/reference ratio were plotted on abscissa against clone positions on the ordinate.

The ability of 1 Mb array used in this study to discriminate single copy number changes has been validated and the thresholds for copy number changes determined (McCabe et al., [@b15]). Briefly, the threshold for single copy loss or gain was defined as being greater than three standard deviations from the average test/reference ratio of autosomal clones in a series of normal male/female hybridizations, which is equivalent to a log~2~ ratio of greater magnitude than −0.21 for loss and greater than +0.18 for gain. Homozygous deletions were defined as log~2~ ratio of −1.0 or below. The threshold for high-level amplification was set to the log~2~ value of +1.80 or greater (equivalent to a copy number gain of five or more). The raw data files of the array-CGH including relevant clinical and histopathological data have been submitted to gene expression omnibus archives <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE56884>.

A copy number change was considered significant when a minimum of two adjacent clones were altered. In some cases, although the copy number deviation did not reach the threshold, the same extent of deviation from the baseline was observed for many consecutive clones. These cases were judged as having losses or gains affecting a subpopulation of tumor cells resulting in the intermediate value. Chromosomes X and Y were excluded from the analysis as hybridizations were sex-mismatched for the purpose of hybridization quality control. Reproducibility of the results was confirmed by repeating the experiments in selected cases (not shown). Normalization was done against the 10 Mb panel of clones in each subarray.

Quantification of Copy Number by qPCR
-------------------------------------

Certain recurrent chromosomal alterations detected by array-CGH were selected for further validation using the TaqMan CopyNumber Assay following the manufacturer\'s protocol (Applied Biosystems). Assays were selected for two recurrently altered regions, that is, gains on 2p15--16.3 encompassing the *BCL11A*, *REL*, *PEX13*, *USP34*, *XPO1*, *COMMD1*, and *OTX1* genes and 19q13.2 covering the *MAP4K1* gene (not shown). The target assays for *BCL11* (Hs02846256_cn), *REL* (Hs01779268_cn), *PEX13* (Hs04585064_cn), *USP34* (Hs00679286_cn), *XPO1* (Hs03394660_cn), *COMMD1* (Hs02311388_cn), *OTX1* (Hs01242264_cn), and *MAP4K1* (Hs00189955_cn) were labeled with 6-carboxyfluorescein (FAM) dye whereas the reference gene RNase P (cat. no. 4403328) was labeled with VIC.

The reactions were set up and run on a 96-well plate using a real-time PCR machine (StepOne plus, Applied Biosystems) and a standard amplification method with the following cycling conditions: 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec, and 60°C for 1 min. To enable normalization of the input target DNA added to each well, the internal control RNase P gene was amplified in parallel in the same well along with the target gene and under identical thermal cycling conditions. Each reaction was run in triplicate, and each experiment was repeated twice.

Amplification data for determination of copy numbers were analyzed using the Sequence Detection Software SDS 2.2 (Applied Biosystems). The target gene data were normalized to RNase P (which is always two copies/genome) and calibrated to normal-pooled blood DNA (Promega) which is supposed to have two copies for the gene of interest. Results were exported as text file and analyzed in the CopyCaller software V1.0 (Applied Biosystems) for target gene copy number prediction. DNA for PCR analysis was available from 53 of the 81 tumors (Supporting Information Table[2](#tbl2){ref-type="table"}). Raw data results from the qPCR analyses of copy numbers from all analyzed cases are given in Supporting Information Table[3](#tbl3){ref-type="table"}.

###### 

The Most Frequently Detected (≥20%) Alterations in the Tumor Groups Analyzed by Array-CGH

  Alteration[a](#tf2-1){ref-type="table-fn"}   Chromosomal region   No of cases (%)              *P*-value[b](#tf2-2){ref-type="table-fn"}                                                                                                
  -------------------------------------------- -------------------- ---------------------------- ------------------------------------------- ---------------- ----------------- --------------------------------------------------------- -------------------
  1p loss                                                                                                                                                                                                                                 
   Subregion FL                                1p35.3--36.11        RP3--398I9//RP3--437I16      8 (53)                                      5 (17)           3 (10)            **0.02**                                                  ns
   Subregion tDLBCL                            1p36.32--36.33       CTB-14E10//RP1--37J18        6 (40)                                      11 (38)          2 (7)             ns                                                        **0.01**
   Subregion de novo DLBCL                     1p36.32--36.12       CTB-14E10//RP11--418J17      0--9 (0--53)                                1--11 (3--38)    2--5 (7--17)      ns-**0.008--0.0001**-ns[c](#tf2-3){ref-type="table-fn"}   ns-ns-**0.01**-ns
  2p gain                                                                                                                                                                                                                                 
   Subregion FL                                2p15--16.3           RP11--19A8//RP11--52F10      3 (20)                                      6--12 (21--41)   1 (3)             ns                                                        ns**−0.001**
   Subregion tDLBCL                            2p15--16.1           RP11--260K8//RP11--261A24    3 (20)                                      12 (41)          1 (3)             ns                                                        **0.001**
  6q loss                                                                                                                                                                                                                                 
   Subregion FL                                6q23.2--24.1         RP11--557H15//RP11--15H7     3 (20)                                      7--8 (24--28)    9 (31)            ns                                                        ns
   Subregion tDLBCL                            6q16.3--16.3         RP11--117M4//RP3--449G2      1 (7)                                       9 (31)           11--12 (38--41)   ns                                                        ns
   Subregion de novo DLBCL                     6q16.3--22.1         RP3--449G2//RP3--383B8       0 (0)                                       7--9 (24--31)    12 (41)           **ns-0.02**                                               ns
  8q gain                                                                                                                                                                                                                                 
   Subregion FL                                8q12.2--12.2         RP11--35A5//RP3--491L6       8 (53)                                      9--10 (31--34)   1 (3)             ns                                                        **0.01--0.005**
   Subregion tDLBCL                            8q12.2--12.2         RP11--35A5//RP11--35A5       8 (53)                                      10 (34)          1 (3)             ns                                                        **0.005**
  13q loss                                                                                                                                                                                                                                
   Subregion FL                                13q31.3--32.1        RP11--632L2//RP11--318K19    3 (20)                                      6 (21)           0--1 (0--3)       ns                                                        **0.02--0.05**
   Subregion tDLBCL                            13q21.1--21.31       RP11--516G5//RP11--67L17     1--2 (7--14)                                8 (28)           2 (7)             ns                                                        ns
   Subregion de novo DLBCL                     13q21.32-21.33       RP11--424E21//RP11--393H6    2 (14)                                      6--7 (21--24)    2 (7)             ns                                                        ns
  15q loss                                                                                                                                                                                                                                
   Subregion 1 tDLBCL                          15q24.1--24.1        RP11-8P11//RP11--414J4       1 (7)                                       8 (28)           1 (3)             ns                                                        **0.03**
   Subregion 2 tDLBCL                          15q26.1--26.3        RP11--326A19//CTB-154P1      1 (7)                                       8 (28)           1 (3)             ns                                                        **0.03**
   Subregion de novo DLBCL                     15q21.1--21.1        RP11--151N17//RP11--151N17   2 (14)                                      7 (24)           5 (7)             ns                                                        ns
  17q gain                                                                                                                                                                                                                                
   Subregion 1 tDLBCL                          17q21.33-21.33       RP11--94C24//RP11--506D12    0 (0)                                       8 (28)           0 (0)             **0.04**                                                  **0.004**
   Subregion 2 tDLBCL                          17q22--23.1          RP11--19F16//RP11--178C3     0 (0)                                       8 (28)           0--2 (0--7)       **0.04**                                                  **0.004**-ns
  18q gain                                                                                                                                                                                                                                
   Subregion FL                                18q21.1--21.32       RP11--116K4//RP11--396N11    8 (53)                                      7--8 (24--28)    10--11 (34--38)   ns                                                        ns
   Subregion tDLBCL                            18q21.32-21.32       RP11--396N11//RP11--396N11   8 (53)                                      8 (28)           10 (34)           ns                                                        ns
   Subregion de novo DLBCL                     18q12.3--21.32       RP11--486C18//RP11--350K6    6--8 (21--28)                               6--7 (21--24)    11 (38)           ns-ns-**0.04**-ns                                         ns
  19p loss                                                                                                                                                                                                                                
   Subregion FL                                19p13.3--13.11       CTC-546C11//CTC-260F20       7 (47)                                      3--4 (10--14)    0 (0)             **0.02--0.03**                                            ns
   19q loss                                                                                                                                                                                                                               
   Subregion FL                                19q13.2--13.43       CTB-186G2//GS1--1129C9       7 (47)                                      4 (14)           0 (0)             **0.03**                                                  ns
  22q loss                                                                                                                                                                                                                                
   Subregion FL                                22q11.21-13.2        XX-p273a17//RP1--85F18       7 (47)                                      6 (21)           0 (0)             ns                                                        **0.02**
   Subregion tDLBCL                            22q11.21-13.2        XX-p273a17//RP1--85F18       7 (47)                                      6 (21)           0 (0)             ns                                                        **0.02**
  No of tumors                                                                                   **15**                                      **29**           **29**                                                                      

Subregions refer to the most commonly occurring alteration defined by FL, tDLBCL, and dnDLBCL, respectively (see [Fig. 1](#fig01){ref-type="fig"}); FL, follicular lymphoma; tDLBCL, transformed diffuse large B-cell lymphoma; dnDLBCL, de novo DLBCL; ns, not significant.

Fishers exact test, significancy is indicated in bold.

Statistical analysis of possible outcomes between the two groups.

![Skyline profiles showing the alterations identified by array-CGH in (A) FL prior to transformation, (B) tDLBCL as well as in (C) dnDLBCL tumors. Gains are indicated in red and losses in green. The blue lines indicate the threshold for alterations identified in at least 20% of the tumors. The arrow in (B) pinpoints 2p amplifications encompassing, among others, the *BCL11A* and *REL*-genes. \[Color figure can be viewed in the online issue, which is available at <http://wileyonlinelibrary.com>.\]](gcc0053-0750-f1){#fig01}

###### 

Chromosomal Alterations Identified in Transformed Lymphomas

  Tumor no   Case no   Diagnosis   Abberations[a](#tf3-1){ref-type="table-fn"}
  ---------- --------- ----------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  45         44:1      DLBCL       −6p22.3
  46         44:2      FL          −6p22.3
  47         45:1      FL          +2p16.1-15, −5q15-q23.2, +6p21.3-12.1, +7, +8, +10p14, −16p13.1-11.2
  48         45:2      DLBCL       +1pter-36.2, **+2p16.1-14**, −5q15-23.2, +6p21.3-12.1, +7, +8, −9, +10pter-11.2, +11pter-12, +11q14.2-qter, −13pter-q12.3, −16p13.1-11.2, −17p, −18pter-11.2, +18p11.2-qter, −19p13.2-12
  49         46:1      FL          --
  50         46:2      DLBCL       −1pter-31.1,+1q21.3-24.3, −3p21.3-21.2, −3q13.3-22.1, −4q, −5pter-p14.1,+7p22.1-14.3, +7q22.1-qter, −8p, +8q13.2-qter,+9q, −11q12.1-13.3, −15, −17p, −19, −20q,+21, −22
  51         47:1      FL          --
  52         47:2      DLBCL       +1q21.1-25.3, +5p, −6q23.3-25.2,+12q12-21.1, −16q12.1-23.3
  53         48:1      FL          −1pter-33, +1q25.3-32.1, −1q41-42.3, +2p21-16.2, −3p26.1-25.2, −4pter-16.1, −6p22.1-21.1,+7p22.1-qter,+8,
  54         48:2      DLBCL       −1pter-33, +1q25.3-32.1, −1q41-42.3, +2p21-16.2, −3p26.1-25.2,+4p, −6p22.1-21.1,+7p22.1-qter,+8, +9, −10q, −11, +12, −13, +14, −15q, + 17p, +17q, −20q
  55         49:1      FL          +3p21.3-21.1, +8q12.1-12.3, + 11
  56         49:2      DLBCL       −1pter-36.2, +3p21.3-21.1, −6p22.1-21.3, −6q13-24.1, +8q12.1-12.3, −9p21.3, −9p.21, −9q33.2-qter, +11, +12p13.3-12.3, −17pter-p.11.2, +17q12-21.3, −17q23.1-25.3, +18pter-q21.3
  57         50:1      FL          +8p11.2-12.1, −8q21.2-22.1, −10q22.2-25.1, −20q11.2-qter
  58         50:2      DLBCL       −5q13.3-14.1, −9p21.2-22.1, +9p12-21.2, +12, −14q21.3-22.3
  59         51:1      FL          −1pter-36.2, +1q, +3, + 4p15.3, −4q13.2-21.2, +5, +6pter-21.1, +7, +9, −13q12.3-12.1, −16q21, +18pter-q21.3, −22
  60         51:2      DLBCL       −1pter-33, +1q, +3, +4p15.3, +5, +6pter-21.1, +7, +9, −11pter-13, −12q23.2-qter, −13q12.3-14.3, −15q23, −16q21-23.1, +18pter-q22.1, −19q, −20, −22
  62         53:1      FL          −1pter-12, −4pter-16.1, −7q21.1-22.1, +7q22.1-31.33, +9p13.2-21.1, −11p12-q14.1, +18, −20q, −22
  63         53:2      DLBCL       −1pter-12, +2p-q14.2, −2q23.3-qter, −4pter-16.1, −6p22.1-21.1, −7q21.1-22.1, +7q22.1-31.3, +9p13.2-q21.1, −11p12-q14.1, −15, −17pter-q21.3, +17q21.3-qter, +18, −20q, −22
  65         55.1      FL          +1pter-36.2, +1q, +11, −13q21.1-34, +18, +19
  66         55:2      DLBCL       +1pter-36.2, −3p13-q21.1, −8pter-23.2, −9pter-21.1, +11, −13q21.1-34, +16p13.11-q12.1, + 18, +19
  67         56:1      FL          −1p34.2-12, −4p16.2-15.1, −7q35-36.3, −9pter-13.3, + 9p13.3-qter, −12pter-q13.1, −13, −14q24.3-31.1, −18, −22
  68         56:2      DLBCL       +1pter-p34.2, −1p34.2-12, −2q31.1-32.2, −4p16.2-15.1, −5q13.2-14.3, −7q35-36.3, −9pter-13.3, +9p13.3-qter, −10q23.1-23.3, −12pter-q13.1, −13, −14q24.3-13.1, −17p, +19q, −22
  69         57:1      FL          −1p36.2-35.1, +8, +11q24.2-qter
  70         57:2      DLBCL       −1p36.23-35.1, +6p22.3, +8, +11q24.2-qter, +12p13.3-12.3
  71         58:1      FL          −3p26.1-25.1, +3p25.1-22.1, −6q12-24.1, +8, −9p22.1-21.3, −17, −19
  72         58:2      DLBCL       **+2p16.3-14**, +6pter-q12, −6q12-24.1,+7, −9p22.1-21.3, +13q33.3-34, −17, −19
  73         58:3      DLBCL       **+2p16.3-14**, +6pter-q12, −6q12-24.1, +7, −9p22.1-21.3, +13q33.3-34, −17, −19
  74         59:1      FL          −1pter-23.3, −4pter-15.2, −7pter-21.3, −11p13-q14.1, −12q24.1-qter, −17, +18, −19, −22
  75         59:2      FL          −1pter-32.3, +1q31.1-qter, +2p23.3-15, −17pter-p12, +18, −19, −22
  76         59:3      FL          −1pter-32.3, +1q23.3-24.2, **+2p16.3-14**, −3pter-25.3, +3q22.2-qter, −4q31.2-34.1, −6q22.3-24.1,+7q21.1-31.1, +8q, −9p23-21.1, +9q21.1, +11pter-11.2, +11q22.3-23.3, −11q23.3-qter, −13q31.3-qter, −14q21.3-24.2, +15pter-15.1, −15q15.1-qter, −17p, +18
  77         59:4      DLBCL       −1pter-32.3, +1q23.3-24.2, −2p23.1-16.3, **+2p16.3-14**, −3pter-25.3, +3q22.2-qter, −4p12-q21.1, −4q31.2-34.1, +6pter-24.3, −6p21.1-12.2, −6q14.1-25.2, +7pter-14.1, +7q11.2-32.1, +8q, +9pter-22.3, −9p22.3-21.3, +9q21.1, +9q22.3-33.2, +10p, −10q26.1-qter, +11pter-15.1, +11q22.3-23.3, −11q23.3-qter, −13(homozygot), +15pter-q15.1, −15q15.1-qter, −17p, +18q21.3-23, −19, −22
  78         60:1      FL          −1pter-34.3,+1q22-qter, +11pter-11.2, −14q24.2-qter, −15q14-21.1, −19
  79         60:2      FL          −1pter-34.3, +1q22-qter, +11pter-11.2, −14q24.2-qter, −19, −22
  80         60:3      FL          −1pter-32.3, +1q21.3-qter, +2pter-12, +3p25.1-qter, +4q31.2-qter, +5, −6pter-21.1, +7, +8, +9q21.1-33.3, −10q21.3-qter, −11q12.1-qter, +12q13.3-21.3, +13, −14q23.3-qter, −16, −17p, −19, −22
  81         60:4      FL          −1pter-32.3, +1q21.3-qter, +2pter-12, +4q31.2-qter, +5, −6pter-21.1, +7, +8, +9q21.1-33.3, −10q21.3-qter, −11q12.1-qter, −12q13.3-21.3, +13, −14q23.3-qter, −16, −17p, −19, −22
  82         60:5      DLBCL       −1p, +1q21.2-qter,+2pter-12, +4q31.2-qter, +5, −6p22.3-qter, +7, +8, +9q21.1-33.3, −10, +12p13.1-q21.3, −14q31.3-qter, −17p, +20, −22

High level amplification is indicated in bold; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma.

Immunohistochemistry
--------------------

Formalin-fixed paraffin embedded sections (4-µm thick) from seven cases with detected 2p amplification (cases 12, 21, 23, 31, 45, 58, and 59), 5 DLBCL GC type without 2p changes (cases 4, 6, 16, 17, and 18), 5 DLBCL non-GC type without 2p changes (cases 2, 7, 8, 13, and 15) and six cases of low grade FL (control samples) were immunostained using Bond-Max system (Leica Newcastle Upon Tyne, UK). Deparaffinization was done at 75°C using Bond Dewax solution. Dehydration was performed using ethanol, and rehydration by Bond wash solution 10× concentrate. Ethylenediaminetetraacetic acid (EDTA) buffer pH 8.9--9.1 (Bond Epitope Retrieval Solution 2 catalog no. AR9640) was used for antigen retrieval at 25°C.

Slides were incubated with polyclonal rabbit anti-human BCL11A \[N-terminus, LS-B3530-50, Nordic BioSite (1:600)\] and mouse monoclonal anti-human REL \[N-terminus, Santa Cruz Biotechnology (1:800)\] for 20 min at room temperature. Polymeric horseradish peroxidase-anti-mouse rabbit IgG reagent was used and staining was visualized with diaminobenzidine (Bond Polymer Refine Detection Kit, catalog no. DS 9800). Images were acquired using the Olympus BX51 microscope and digital camera Olympus U-TV0.5XC-3.

Statistical Analysis
--------------------

Differences between the studied groups were evaluated by statistical analysis using the software system SigmaPlot v.11.0 (Systat Software, Inc., CA). The Fisher\'s exact test (two tail) was applied to determine difference in studied groups. Results were considered as statistically significant with *P*-values less than 0.05.

Results
=======

Overall Whole Genome CGH Array Alterations
------------------------------------------

The tumors were categorized into (a) FL prior to transformation, (b) tDLBCL, and (c) dnDLBCL (Table[2](#tbl2){ref-type="table"}). The dnDLBCL tumors were furthermore divided into GC and non-GC categories based on immunohistochemistry according to Hans algorithm (Hans et al., [@b10]). All tDLBCL, both the paired and nonpaired samples, were of GC immunophenotype.

Studies based on paired tumor samples are of the highest importance to outline chromosomal changes occurring during the transformation from FL to tDLBCL. However, samples where both FL and tDLBCL counterparts are available from the same patient are scarce, and we have therefore analyzed also samples of tDLBCL, with known FL history, but no available diagnostic FL samples. Alterations detected in each tumor category are shown in [Figure 1](#fig01){ref-type="fig"}.

In general, gains were more common than losses and more aberrations were found in tDLBCL than in dnDLBCL. The selected alterations were further narrowed down in each tumor group into a minimal altered region defined by the most frequently occurring aberration. The regions of greatest significance in each group are listed in Table[2](#tbl2){ref-type="table"}. The significance of each alteration was evaluated in tDLBCL vs. FL as well as tDLBCL versus dnDLBCL.

Alterations of Importance for the Transformation Process
--------------------------------------------------------

In an attempt to outline chromosomal changes occurring during histological transformation from FL to tDLBCL, we found that gains at 17q21.33 (*P* \< 0.04) and 17q22--23.1 (*P* \< 0.04) were statistically more often seen in the tDLBCL (Table[2](#tbl2){ref-type="table"}). We also found a tendency for higher frequency of losses at 6q16.3 (*P* \< 0.08) (Supporting Information Table[1](#tbl1){ref-type="table"}). This region, encompassing among others the *SIM1*, *RNAH*, *GRIK2*, and *DJ467n11.1* genes, is frequently deleted in hematological malignancies including DLBCL of both de novo and transformed origin (Berglund et al., [@b1]; Thelander et al., [@b27]).

When comparing the alterations detected in the tDLBCL to those found in the dnDLBCL (Table[2](#tbl2){ref-type="table"}), changes of interest were losses of 1p36.32--36.33 (*P* \< 0.01), 13q31.3--32.1 (*P* \< 0.02), 15q24.1 (*P* \< 0.03), 15q26.1--26.3 (*P* \< 0.03), and 22q11.21-13.2 (*P* \< 0.02), and gains in 2p15--16.1 (*P* \< 0.001), 8q12.2 (*P* \< 0.005), 17q21.33 (*P* \< 0.004), and 17q22--23.1 (*P* \< 0.004).

Early and Late Events During Transformation
-------------------------------------------

Paired samples from 15 patients (cases 44--51, 53, and 55--60) with two or more tumors collected throughout the course of transformation were available, permitting a more thorough analysis of the progression of specific chromosomal events during the transformation process. The aberrations identified in each individual tumor are listed in Table[3](#tbl3){ref-type="table"}, and the most commonly occurring alterations (detected in two or more paired tumors) are given in Supporting Information Table[4](#tbl4){ref-type="table"}. Gain of 2p15.1--16.1 was among the most frequently changed regions (29% of FL and 38% of tDLBCL).

###### 

The Most Frequent Array-CGH Alterations in FL in Relation to the Total Number of Alterations

  Case no   No of alt   −6             +8             −1p            −20q            −10             +1q            −19   −22   −15q            +2p15-16       +7             +6p            +18q            −13q   −17p          −9p21         −14q
  --------- ----------- -------------- -------------- -------------- --------------- --------------- -------------- ----- ----- --------------- -------------- -------------- -------------- --------------- ------ ------------- ------------- ---------------
  46:1      0                                                                                                                                                                                                                                   
  47:1      0                                                                                                                                                                                                                                   
  44:2      1           −6p22.3                                                                                                                                                                                                                 
  49:1      3                          +8q12.1-12.3                                                                                                                                                                                             
  57:1      3                          +8             −1p36.2-35.1                                                                                                                                                                              
  50:1      4                          +8p11.2-12                    −20q11.2-qter   −10q22.2-25.1                                                                                                                                              
  60:1      6                                         −1pter-34.3                                    +1q22qter      −19                                                                                                                         
  60:2      6                                         −1pter-34.3                                    +1q22qter      −19   −22   −15q14-21.1                                                                                                     
  45:1      7                          +8                                                                                                       +2p15-16       +7             +6p21.3-12.1                                                      
  55:1      7                                                                                        +1q                                                                                     +18             −13q                               
  59:2      7                                         −1pter-32                                      +1q31.1-qter   −19   −22                   +2p15-16                                     +18                    −17pter-p12                 
  58:1      7           −6q12-24.1     +8                                                                           −19                                                                                             −17           −9p22-21.3    
  48:1      9           −6p22.1-21.1   +8             −1pter-33                                      +1q25.3-32.1                               +2p15-16       +7p22.1-qter                                                                     
  53:1      9                                         −1pter-12      −20q                                                 −22                                  +7q22.1-31.3                  +18                                                
  56:1      9                                         −1p34.2-12                                                          −22                                                                                −13                  −9pter-13.3   −14q24.3-31-1
  59:1      9                                         −1pter-23.3                                                   −19   −22                                                                +18                    −17                         
  51:1      11                                        −1pter-36.2                                    +1q                  −22                                  +7             +6pter−21.1    +18pter-q21.3                                      
  60:4      18          −6pter-21.1    +8             −1pter-32.3                    −10q21.3-qter   +1q21.3-qter   −19   −22                   +2pter-12      +7                                                   −17p                        −14q23.3-qter
  60:3      19          −6pter-21.1    +8             −1pter-32.3                    −10q21.3-qter   +1q21.3-qter   −19                         +2pter-12      +7                                                   −17p                        −14q23.3-qter
  59:3      20          −6q22.3-24.1   +8q            −1pter32.3                                     +1q23.3-24                 −15q15.1-qter   **+2p14-16**   +7q21.1-31.1                  +18             −13q   −17p          −9p23-21.1    −14q21.3-24.2

Bold indicates high level amplification; FL, Follicular Lymphoma; alt, alteration.

To outline the succession of chromosomal gains or losses during histological transformation, we studied the alterations in relation to number of changes in each individual tumor among the FL-tDLBCL pairs (Tables[4](#tbl4){ref-type="table"} and [5](#tbl5){ref-type="table"}). Losses of 9p, 13q, 14q, and 17p and gains in 2p, 6p, 7q, and 18 were detected in FL tumors with ≥7 alterations (Table[4](#tbl4){ref-type="table"}) and were therefore considered as late events in the FL prior to transformation. In the tDLBCL, losses of 1p, 6p, 6q, 9p, and 14q as well as gains of 1q, 6p, 8q, and 12q were considered as early events as these abnormalities appeared in the tumors with five alterations or less (Table[5](#tbl5){ref-type="table"}). Thus, losses of 9p and 14q as well as gains of 6p were identified as late events in FL prior to transformation and as early in tDLBCL, indicating that genes within these regions may be of importance for the peritransformational phase.

###### 

The Most Frequent Array-CGH Alterations in tDLBCL in Relation to the Total Number of Alterations

  Case no   No of alt   −6p             −9p             −14q             +6p           −1p           +8           −6q            +1q              +12q           +2p15−16          −17p           +7              −19            +1p           −13q           +18q           +17q            −22   −10              −15q            −20q
  --------- ----------- --------------- --------------- ---------------- ------------- ------------- ------------ -------------- ---------------- -------------- ----------------- -------------- --------------- -------------- ------------- -------------- -------------- --------------- ----- ---------------- --------------- ------
  44:1      1           −6p22.3                                                                                                                                                                                                                                                                                                     
  50:2      4                           −9p21.2−22.1    −14q21.3−22.3                                                                                                                                                                                                                                                               
  57:2      4                                                            +6p22.3       −1p36.2--35   +8                                                                                                                                                                                                                             
  47:2      5                                                                                                     −6q23--25.2    +1q21.1--25.3    +12q12--21.1                                                                                                                                                                      
  58:2      8                                                            +6pter-q12                               −6q12--24.1                                    **+2p14--16**     −17            +7              −19                                                                                                               
  55:2      9                           −9pter-21.1                                                                                                                                                                              +1pter-36.2   −13q21.1--34   +18                                                                   
  49:2      14          −6p22.1--21.3   −9p21.3                                        −1pter-36.2   +8q12        −6q13--24                                                        −17pter-11.2                                                                              +17q12--21                                             
  56:2      14                          −9pter-13.3     −14q24.3--13.1                 1p34.2--12                                                                                  −17p                                          +1pter-34.2   −13                                           −22   −10q23.1--23.3                   
  53:2      15          −6p22.1--21.1                                                  −1pter-12                                                                 +2p16-q14.2       −17pter-q21    +7q22.1--31.3                                               +18            +17q21.3-qter   −22                    −15             −20q
  60:5      15          −6p22.3-qter                    −14q31.3-qter    −1p           +8                         +1q21.2-qter   +12p13.1−q21.3   +2pter-12      −17p              +7                                                                                        −22             −10                                    
  45:2      17                          −9                               +6p21-12                    +8                                                          **+2p14--16**     −17p           +7              −19p13.2--12   +1pter-36.2                                                                                        
  46:2      17                                                                         −1pter-31     +8q13-qter                  +1q21.33-24.3                                     −17p           +7p22-14        −19                                                                        −22                    −15             −20q
  51:2      17                                                           +6pter-21.1   −1pter-33                                 +1q                                                              +7              −19q                                                                       −22                    −15q23          −20
  48:2      18          −6p22.1--21.1                                                  −1pter-33     +8                          +1q25.3--32.1    +12            +2p16--21                        +7p22.1-qter                                                               +17q                  −10              −15q            −20q
  59:4      30          −6p21.1--12.2   −9p22.3--21.3                    +6pter-24.3   −1pter-32.3   +8q          −6q22.3--24    +1q23.3--24.2                   **+2p14--16.3**   −17p           +7pter-14.1     −19                          −13            +18q21.3--23                   −22   −10q26.1-qter    −15q15.1-qter   

Bold indicate high level amplification; tDLBCL, transformed diffuse large B-cell lymphoma; alt, alteration.

Lymphoma of GC and Non-GC Origin
--------------------------------

Clinically, non-GC origin of DLBCL is considered to be more aggressive than the GC subtype (Hans et al., [@b10]). Among the GC DLCBL, the transformed tumors have a less favorable clinical outcome compared with the de novo cases. In our series, all tDLBCL had GC-related immunophenotype. An attempt was made to compare the alterations identified in GC (10 tumors) vs. non-GC (19 tumors) subcategories of dnDLBCL (Supporting Information Table[1](#tbl1){ref-type="table"}). The statistical analysis indicated that a deletion of 1p36.32--36.33 is more common in the GC group (20% vs. 0%, *P* \< 0.053). However, in our study a relatively small number of tumors was available for analysis in the two groups studied and was therefore not considered further. The importance of this alteration could be investigated in larger tumor series.

Furthermore, only one of the dnDLBCL tumors showed 2p amplification and this was interestingly of GC origin (Supporting Information Table[1](#tbl1){ref-type="table"} and [Figs. 1](#fig01){ref-type="fig"}A and [1](#fig01){ref-type="fig"}B). When comparing the CGH-derived dnDLBCL with the tDLBCL (which are all of GC origin) regarding amplification of 2p15--16, the difference is not significant (*P* \< 0.12), indicating that this alteration may reflect cell of origin distribution (GC origin) rather than an oncogenic event related to transformation. However, our data on subsequent FL-tDLBCL tumors strongly indicate an involvement of this region in the transformation. This aspect is therefore further discussed below.

Amplification of 2p15--16
-------------------------

A gain of 2p15--16 was seen in 3/15 (20%) FL, 12/29 (41%) tDLBCL and in 1/29 (3%) of the dnDLBCL (GC origin) tumors (Table[2](#tbl2){ref-type="table"}). Interestingly, the only dnDLBCL tumor that showed a 2p amplification was of GC origin (Supporting Information Table[1](#tbl1){ref-type="table"} and [Figs. 1](#fig01){ref-type="fig"}A and [1](#fig01){ref-type="fig"}B), as is all tDLBCL. This could indicate that this DLBCL was in fact of transformed origin with a previously unknown FL counterpart. Notably, the only alteration that was detected as a high level amplification encompassed 2p15--16.3 carrying, among others, the *BCL11A*, *REL*, *PEX13*, *USP34*, *XPO1*, *COMMD1*, and *OTX1* genes. These were therefore subjected to further analysis using qPCR (Table[6](#tbl6){ref-type="table"} and Supporting Information Table[2](#tbl2){ref-type="table"}). The 16 lymphoma samples showing more or less than two copy numbers of the analyzed genes in 2p15--16.3 are listed in Table[6](#tbl6){ref-type="table"}. The highest level of amplification within this region was seen in *USP34* (3--20 times) whereas the lowest level was noted for *BCL11A* (3--8 times). The most frequently amplified gene among the analyzed tumors was *PEX13* (in eight tumors) and the least occurring was *OTX1* (in five tumors; Case 59 was excluded from the comparison as DNA was not available for all the analyses).

###### 

Gene Copy Number Estimated by Quantitative Real-Time PCR \[Color table can be viewed in the online issue, which is available at <http://wileyonlinelibrary.com>.\]

                 Detected copy number                              
  ------ ------- ---------------------- ---- ---- ---- ----- ----- -----
  2      DLBCL   2                      2    3    1    1     1     1
  5      DLBCL   2                      2    2    1    2     2     1
  7      DLBCL   2                      1    2    1    2     1     1
  12     DLBCL   2                      3    3    3    2     3     2
  17     DLBCL   2                      2    2    1    2     2     2
  20     DLBCL   3                      3    3    3    3     3     2
  21     DLBCL   7                      9    8    10   \>8   6     \>9
  23     DLBCL   3                      4    4    4    4     \>4   4
  31     DLBCL   3                      3    3    3    3     3     3
  45:1   FL      2                      2    3    2    2     2     2
  45:2   DLBCL   3                      10   16   20   6     9     8
  58:2   DLBCL   8                      7    12   13   8     9     2
  58:3   DLBCL   6                      7    10   11   9     9     3
  59:2   FL      3                      3    na   na   na    na    na
  59:3   FL      7                      9    na   na   na    na    na
  59:4   DLBCL   6                      6    na   na   na    na    na

DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; Losses are indicated in green and gains in red; na, DNA not available.

Discussion
==========

Alterations of Importance for the Transformation Process
--------------------------------------------------------

In an attempt to outline chromosomal regions that are lost or gained during histological transformation from FL to tDLBCL, we performed a comparison of the alterations identified by array-CGH in three studied groups, that is, FL, tDLBCL as well dnDLBCL (Supporting Information Table[1](#tbl1){ref-type="table"}). A comparison between the tDLBCL and dnDLBCL indicates alterations that differ between the transformed and the de novo cases and is therefore indicative of transformation as well as de novo specific alteration. Using a Fisher\'s exact test, we identified statistically significant regions of interest (Table[2](#tbl2){ref-type="table"}) among which amplification of 2p15--16 appeared to be the most significant (*P* \< 0.001). This alteration has mainly been reported in the group of GC-DLBCL and never observed in the ABC subtype (Lenz et al., [@b12]). However, it should be noted that the dnDLBCL predominantly (19/29 = 66%) belong to the non-GC group and a comparison between dnDLBCL and tDLBCL may rather reflect the GC vs. non-GC cell of origin. The 2p15--16 region was the only one in our tumor setting where a high level amplification was detected and was therefore studied further (discussed below).

We also examined the difference in alterations between the FL and the tDLBCL groups. However, these two groups are genetically linked by clonal evolution from FL to tDLBCL meaning that alterations of importance for the transformation process appear already in the FL and not only in the tDLBCL counterpart (Berglund et al., [@b1]). Therefore, alterations of importance for the initiation of transformation would appear already within the FL counterpart, and may not be identified as statistically different between these two subgroups studied and could therefore be missed. The chromosomal regions that appeared as statistically significant (Table[2](#tbl2){ref-type="table"}) may rather indicate alterations of importance for the early phase of tDLBCL rather than for the initiation of the transformation process.

Early tDLBCL Phase
------------------

Interestingly, we noted that a gain encompassing 17q21.33 was exclusively found in tDLBCL (*P* \< 0.004)(Table[2](#tbl2){ref-type="table"}) indicating that an upregulation of this region may be of greater importance later in the transformation process rather than in the initiation phase, as it was not observed in the FL counterpart. It has previously been speculated that a gain of 17q, and in particular 17q21, is of importance in the histological transformation of FL to tDLBCL (Martinez-Climent et al., [@b14]; Nanjangud et al., [@b17]). One possible candidate, located in 17q21.33, that could be considered of importance in tumorigenesis is the *NME1/NM23* gene that is involved in the transcriptional regulation of both *NMYC* and *MYC*. High expression of *NME1/NM23* has been associated with decreased metastasis in breast cancer as well as in melanoma. However, in non-Hodgkin lymphoma it has been associated with adverse outcome (Niitsu et al., [@b18]) and is therefore a good target for further investigation.

The Peri-Transformation Phase
-----------------------------

We found that loss of 6q16.3-24.1 is common during the transformation process from FL to tDLBCL as shown in other studies (Berglund et al., [@b1]; Nanjangud et al., [@b17]; Eich et al., [@b5]; Lossos and Gascoyne, [@b13]; Bouska et al., [@b2]). This chromosomal region is large but still very few candidate genes have been identified. In our previous study, we identified loss of 6q16-21 as a transitional change that was more common in tDLBCL than in FL (Berglund et al., [@b1]; Rane et al., [@b22]). This region is also frequently lost in solid tumors and *SEN6A* has been postulated as a tumor suppressor gene (Rane et al., [@b22]). In our setting, the minimal deleted regions at 6q16.3 that was found in the tDLBCL tumors were not observed as lost in the FL tumors (Table[2](#tbl2){ref-type="table"}). The 6q deletions identified in the FL tumors were situated more distal at 6q23.2-24.1 (Table[2](#tbl2){ref-type="table"}). Candidate genes in this region are *TNFAIP3* as well as *PERP* and have earlier been discussed as targets in FL (Henderson et al., [@b11]; Ross et al., [@b23]; Schwaenen et al., [@b24]; Bouska et al., [@b2]).

However, the most striking finding in our study appears to be the amplification of the 2p15-16 that was found to be the most frequently gained region in the peritransformation phase. This will be more thoroughly discussed below.

Other statistically different alterations between the FL and tDLBCL were found, such as losses of 1p35.3-36.11 (*P* \< 0.02), 19p13 (*P* \< 0.02), and 19q13 (*P* \< 0.03). Losses of these regions were more common in the FL than in the tDLBCL counterpart (Table[2](#tbl2){ref-type="table"}). This could be interpreted as if genes encompassed by these alterations are not directly involved in the initiation of the transformation. It is interesting to note that none of the dnDLBCL displayed any such alterations in chromosome 19.

As mentioned earlier, loss of 9p and 14q as well as gain of 6p were noted as late FL events and as early tDLBCL events (Tables[4](#tbl4){ref-type="table"} and [5](#tbl5){ref-type="table"}) indicating involvement in the peritransformational phase. Loss of 9p and gain of 6p were also more frequent in tDLBCL compared to FL in the paired samples. The *CDKN2A/P14ARF* gene located at 9p21 is a strong candidate and has previously shown to be involved in the transformation of FL (Lossos and Gascoyne, [@b13]). Furthermore, the *CCND3* gene at 6p21 has previously been suggested to be involved in the transformation from FL to tDLBCL (Martinez-Climent et al., [@b14]). In a recent paper by Okosun et al. ([@b19]) on transformation from FL to tDLBCL, it is stated that no single compelling genetic event could be identified as responsible for transformation but that distinct genetic alterations may prompt the onset of aggressive disease. However, in our series of subsequent and paired tumors, we strongly believe that an upregulation of genes in 2p15--16 could be such a translocation prone alteration.

Amplification of the Region 2p15-16
-----------------------------------

When tDLBCL were compared with dnDLBCL, the statistically most significant change by array-CGH was an amplification of 2p15--16.3 (*P* \< 0.001) encompassing, among others, the *BCL11A*, *REL*, *PEX13*, *USP34*, *COMMD1*, and *OTX1* genes. This region was found to be most frequently gained in the FL samples collected prior to transformation as well as the first tDLBCL samples immediately after transformation. Notably, in all tDLBCL tumors, a high level amplification was observed indicating its significance in the transformation process. A discussion has previously been raised concerning if the true target gene in this amplicon is *REL*, *BCL11A* or both. *REL* has been shown to be more frequently amplified and it may therefore play a more important role than *BCL11A* in the pathogenesis of the tDLBCL (Fukuhara et al., [@b8]). This hypothesis is also supported by our investigation using qPCR which showed a higher level of amplifications of *REL* compared to *BCL11A* in cases with 2p15--16.3 amplifications (Table[6](#tbl6){ref-type="table"}). In case 31, equal copy numbers were detected in *REL* and *BCL11A* (i.e., three copies of each), whereas in cases 12, 21, 23, 45, and 59 the copy numbers of *BCL11A* ranged from 2 to 7 copies whereas *REL* showed 2 to10 copies (Table[6](#tbl6){ref-type="table"}). In case 45:2, the difference was highest with three copies of *BCL11A* and 10 copies of *REL* indicating that *REL* may be the driver gene. In case 59, tumors 2 and 4 showed equal copy numbers that is, 3 and 6, respectively. However, the intermediate tumor 59:3 showed a difference of seven copies for *BCL11A* and nine copies of *REL*. Interestingly, this tumor is a FL just prior to transformation to tDLBCL.

However, we also investigated the *PEX13*, *USP34*, *XPO1*, *COMMD1*, and *OTX1* genes included in the 2p15--16.3 amplicon. We noted that the highest level of amplification was seen for *USP34* that was amplified up to 20 times, showing the highest amplification in three cases (tumors 21, 45:2, and 58:2). *USP34* has previously showed to be involved as a negative regulator of the NF-κB signaling pathway in lymphocytes; however, it is most extensively studied in T-cells (Poalas et al., [@b21]). *PEX13* appeared as the most commonly amplified (eight cases) whereas *OTX1* was the least commonly amplified (four cases) even though the level of amplification of *OTX1* was in general higher compared with *BCL11A*. The OTX1 protein acts as a transcription factor and has been suggested to be of importance in B-cell maturation (Omodei et al., [@b20]) making it an interesting candidate for further analysis of involvement in the transformation process. Notably, in cases 45:1 and 45:2 (Table[6](#tbl6){ref-type="table"}), representing the FL and tDLBCL counterparts from the same patient, the biggest increase in copy numbers were noted for *USP34* (from 2 to 20 copies), *PEX13* (from 3 to16 copies), and *REL* (from 2 to10 copies), indicating the importance of these three genes for transformation.

Taken together, these findings indicate that the *REL* gene can be of greater importance than *BCL11A* as a driver gene for the transformation process from FL to tDLBCL. However, the other genes within the 2p15-16.3 amplicon could also be of importance for the tumor transformation as all of them show a significant level of amplification. Their importance for the transformation process remains to be illuminated. In cases 45, 58, and 59, more than two subsequent tumors were available for further analysis during the transformation process. In two of these (45 and 58), the amplification of 2p15-16 was first seen in the tDLBCL whereas it was absent in the FL prior to transformation ([Fig. 2](#fig02){ref-type="fig"}). However, in case 59, amplification was seen already in the FL stage of disease (tumor 59:3), indicating that this alteration occurs early in the transformation process and drives the transformation rather than being a result of it. Notably, a tendency to amplification was seen already in tumor 59:2 ([Fig. 2](#fig02){ref-type="fig"} and Table[6](#tbl6){ref-type="table"}) which is the FL tumor preceding the FL prior to transformation (59:3). Therefore, we suggest that amplification of 2p15-16 could be associated with the transformation process and that this alteration may possibly serve as a biomarker for the detection of FL with a potential to transform to tDLBCL as well as to discriminate between dnDLBCL and tDLBCL ([Figs. 3](#fig03){ref-type="fig"} and [4](#fig04){ref-type="fig"}).

![(A) Array-CGH profiles of chromosome 2 from subsequent tumors from cases 45, 58, and 59 showing progression with high level amplification of 2p15-16, encompassing the *BCL11A* and *REL* genes. The dotted line indicates the transformation from FL to tDLBCL. The blue arrow indicates the amplification encompassing the *BCL11A* and *REL* genes. (B) qPCR showing copy numbers of *BCL11A* and *REL* in the subsequent tumors from cases 45 and 59, respectively. \[Color figure can be viewed in the online issue, which is available at <http://wileyonlinelibrary.com>.\]](gcc0053-0750-f2){#fig02}

![Genes located within the minimal region of gain in 2p15-p16.1 identified in transformed tumors by array-CGH. The clones flanking the minimal region are indicated below. Genes that have been further investigated by qPCR in this study are indicated in bold. \[Color figure can be viewed in the online issue, which is available at <http://wileyonlinelibrary.com>.\]](gcc0053-0750-f3){#fig03}

![Immunohistochemistry of BCL11A and REL performed on subsequent tumors of transformed lymphoma from cases 45, 58, and 59 showing a correlation between copy numbers by qPCR (left) and the protein expression (right). FL = follicular lymphoma; DLBCL = diffuse large B-cell lymphoma. \[Color figure can be viewed in the online issue, which is available at <http://wileyonlinelibrary.com>.\]](gcc0053-0750-f4){#fig04}

In summary, we identified differential genomic events between dnDLBCL and tDLBCL that may be of importance in the histological transformation from FL to tDLBCL, as well as reflect the GC vs. non-GC cell of origin. The chromosomal region 2p15-16 appeared as a high level amplification in all of the tDLBCL tumors where it was detected, underlining its significance in the transformation process. Notably, it was in one case shown to be amplified already in the FL counterpart prior to the paired tDLBCL tumor, indicating its importance for the peritransformation phase. Taken together, 2p15-16 amplification in lymphoma serve as a marker for early recognition of disease progression and we suggest that *REL*, *PEX13*, and *USP34* may be driver genes rather than *BCL11A* as previously suggested. Furthermore, a gain of 17q21-23 was exclusively detected in tDLBCL, making this region of interest for candidate genes involved in the late transformation process. We also confirm the impact of the TP53-, NF-κΒ−, and CDKN2A pathways in the transformation process from FL to tDLBCL.
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